Answers are grounded in this paper and cite their sources.
Cohort study compares clinical outcomes of fluticasone and budesonide inhalers in COPD, suggesting differences in efficacy.
In this cohort study of new ICS-LABA users with COPD, once-daily dry powder fluticasone furoate-vilanterol inhalers were associated with slightly improved clinical outcomes compared with twice-daily metered-dose budesonide-formoterol inhalers and twice-daily dry powder fluticasone propionate-salmeterol inhalers. Further studies are needed to explore potential intraclass differences among inhalers used to treat COPD.
No takes yet. Share an insight, caveat, or question.
Feldman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: